Kawashima Hidenori
Nihon Rinsho. 2015 Jan;73(1):167-74.
In extremely rare cases, the metastatic lesions of renal cell carcinoma (RCC) spontaneously regress after removal of the primary disease, and thus RCC has been considered to be immunogenic. Thus far, several immunotherapies including cytokine therapy, peptide vaccine and recent immune checkpoints inhibitors have been employed to treat patients with metastatic RCC. In this review, the recent progress in immunotherapy against RCC is surveyed and its future perspective is discussed. Our experimental research on galectin 9 and PINCH as promising immunotherapy targets is also mentioned.
在极为罕见的情况下，肾细胞癌（RCC）的转移病灶在原发疾病切除后会自发消退，因此RCC被认为具有免疫原性。迄今为止，包括细胞因子疗法、肽疫苗以及近期的免疫检查点抑制剂在内的多种免疫疗法已被用于治疗转移性RCC患者。在本综述中，我们调查了RCC免疫治疗的最新进展，并讨论了其未来前景。我们还提到了关于半乳糖凝集素9和PINCH作为有前景的免疫治疗靶点的实验研究。
